NCT03563950View on ClinicalTrials.gov

An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

July 27, 2018

Study Completion Date

July 27, 2018

Conditions
Healthy Participants
Interventions
DRUG

Rifampin

Specified dose on specified days

DRUG

BMS-986224

Specified dose on specified days

Trial Locations (1)

84107

PRA Health Sciences, Salt Lake City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY